about
Separation of doxorubicin and doxorubicinol by cyclodextrin-modified micellar electrokinetic capillary chromatography.Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function.Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979).Effects of doxorubicinol on excitation--contraction coupling in guinea pig ventricular myocytes.The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.Simultaneous measurement of doxorubicin and reduced metabolite doxorubicinol by UHPLC-MS/MS in human plasma of HCC patients treated with TACE.Selective determination of doxorubicin and doxorubicinol in rat plasma by HPLC with photosensitization reaction followed by chemiluminescence detection.Quantification of pegylated liposomal doxorubicin and doxorubicinol in rat plasma by liquid chromatography/electrospray tandem mass spectroscopy: Application to preclinical pharmacokinetic studies.Simultaneous liquid chromatographic determination of doxorubicin and its major metabolite doxorubicinol in parrot plasma.Pharmacokinetics of adriamycin and adriamycinol after intravenous administration of adriamycin to rats with water-deprivation for 48 hours.The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated CellsDoxorubicin and doxorubicinol plasma concentrations and excretion in parotid salivaA sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by rToxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita)Effect of cyclodextrins on the stability of adriamycin, adriamycinol, adriamycinone and daunomycinSimultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometryPharmacokinetics of doxorubicinol in dogsPaclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapiesValidation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients
P921
Q33254305-9EE72323-112A-4BE2-9CBB-4BD5314AF43BQ33575389-0D387DED-6471-4B6D-BE8F-F7292C081E3FQ35553905-8A8B6A86-9235-4F3A-9959-74E8E94E049AQ36135012-BA42D0F7-7CB5-4278-B153-E1359F37C599Q36329890-2C359D56-F123-4C13-804B-151027CA6A9DQ36617222-441447BC-0C00-4233-A063-2765CDDD1F21Q36900281-AF91C50E-EE43-4313-BF63-CB83A98BFB3EQ39570922-1EE71383-9501-4199-A7FC-44B03FC14B18Q40599369-5B9547AC-FCE7-4129-BB7B-0B86932FC14CQ43670397-465D5A12-6095-4B41-904E-FD0F28CCDEA1Q43906042-5096D762-8C85-47FA-A726-F782F1A94A12Q44915048-27853537-59B5-4696-8A21-4A6D743CD0BFQ46143792-62A7A1D0-3903-4BA0-9CC2-DECF62D3F09AQ46678271-251D0E32-1244-462C-BD7C-C9E52645CF32Q46708155-176FD526-78D7-4345-BB3F-70D083615EF4Q48747003-CC0D37D9-9321-4D14-AE32-DA593CDD1B18Q64106342-DE78FD1D-68C9-4F34-803C-CF946A6F0B09Q68202652-34CFA6DE-E016-444D-A9A7-7B97281D7796Q77060232-52777F69-3405-4A25-83CB-56471EE629E7Q79464955-89FB13BA-B4E9-43A5-ADF4-D6A7F3948D9FQ79746850-AF792D99-0341-4ED1-9DFF-4F7917BC0C4FQ80018469-121468E2-0A65-460B-9236-AA2C2C242FA2Q80226923-9EDCDA82-FAA3-4E24-A775-ECA186781A9AQ83154015-9EA3B08C-CF70-4600-A069-B90635888FBFQ87447706-1DD31854-FB11-40A2-991A-BE22B3FA0349
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
doxorubicinol
@en
type
label
doxorubicinol
@en
prefLabel
doxorubicinol
@en
P592
P661
P662
P683
P2017
C[C@H]1[C@H]([C@H](C[C@@H](O1) ...... )C=CC=C5OC)O)([C@H](CO)O)O)N)O
P2067
P231
54193-28-1
P233
CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(CO)O)O)N)O
P234
1S/C27H31NO11/c1-10-22(31)13(2 ...... ,13-,15-,16-,17-,22+,27-/m0/s1
P235
NKZRZOVSJNSBFR-FEMMEMONSA-N
P274
C₂₇H₃₁NO₁₁
P3117
DTXSID70920620
P592
CHEMBL3277946
P652
HUH05KI4CF